Safety and short-term efficacy analysis of breast-conserving surgery combined with intraoperative radiotherapy for early-stage breast cancer
10.3760/cma.j.cn112152-20191217-00815
- VernacularTitle:保乳术联合术中放疗治疗早期乳腺癌的近期疗效及安全性
- Author:
Yang ZHANG
1
;
Yang YANG
;
Xinguang WANG
;
Jian TIE
;
Yingjian HE
;
Jinfeng LI
;
Yuntao XIE
;
Tianfeng WANG
;
Tao OUYANG
;
Zhaoqing FAN
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所 乳腺癌预防治疗中心 恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- Keywords:
Breast neoplasms;
Breast-conserving surgery;
Intraoperative radiotherapy;
Cosmetic effect;
Adverse reaction
- From:
Chinese Journal of Oncology
2020;42(8):682-686
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the safety and short-term efficacy of breast-conserving surgery combined with intraoperative radiotherapy for early-stage breast cancer.Methods:A total of 101 consecutive patients who received breast-conserving surgery plus intraoperative radiotherapy were recruited to summarize the recent follow-up results and clinicopathological data. Univariate analysis and Logistic regression model were used to evaluate the factors affecting the postoperative adverse reactions and cosmetic effects.Results:Among 101 patients, 4 patients had recurrence or metastasis. The 3-years disease free survival rate was 94.9%, and the 3-years cumulative recurrence rate was 5.1%. Univariate analysis showed that the menstrual status and postoperative whole breast radiotherapy were associated with the postoperative adverse reactions ( P<0.05). The T stage and applicator diameter were associated with the cosmetic effect ( P<0.05). Multivariate analysis indicated that the diameter of the applicator ( OR=3.701, P=0.026) and postoperative whole breast radiotherapy ( OR=5.962, P=0.005) were independent factors for the postoperative adverse reactions, and the diameter of the applicator ( OR=2.522, P=0.037) was an independent factor for the cosmetic effect. Conclusion:Breast-conserving surgery combined with intraoperative radiotherapy shows safety and good short-term efficacy in low-risk early-stage breast cancer.
